We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Ananya
Choudhury
ananya.choudhury@nhs.net
Rachel
Reed
rachel.reed@manchester.ac.uk
Malignant neoplasms of female genital organsMalignant neoplasms of male genital organsMalignant neoplasms of urinary tract
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Around 50% of cancer patients with solid tumors receive radiotherapy. However,more than 25% of these patients have tumors that are low in oxygen (hypoxic),and these tumors don’t respond well to radiotherapy. A treatment strategy called CON,which involves breathing oxygen-enriched air and taking an oral drug called nicotinamide,has been shown to improve the effectiveness of radiotherapy for these hypoxic tumors. Currently,there are no approved tests to identify which tumors are hypoxic.
Our team has developed and tested genetic biomarkers that can identify hypoxic tumors in bladder,head and neck,prostate,sarcoma,and lung cancers. These biomarkers can predict whether a patient with bladder cancer will benefit from hypoxia modification using RNA from preserved tumor tissue. The goal of this study is to confirm that these hypoxia biomarkers can predict,in real-time,whether patients with hypoxic tumors in at least two types of cancer will benefit from the hypoxia treatment
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
This will be tumour site dependent Bladder: - Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form. - Unable to tolerate MRI scans. - Pregnancy. Cervix: - Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form. - Unable to tolerate MRI scans. - Pregnancy. Prostate: - Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form. - Unable to tolerate MRI scans.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Manchester and funded by ACTION BLADDER CANCER UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 66335
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
